Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected T
The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.
| Condition(s) | Solid Tumors, Sarcomas |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer. |
| Who can participate | Inclusion Criteria: * Adult men and women ≥18 years of age at the time of signing the ICF with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy \> 3 months * Participants must have histologically confirmed and documented diagnosis of locally advanced unresectable and/or metastatic sarcoma or a selected solid tumor * Participants must be willing to undergo a tumor biopsy prior to start of treatment or provide archived tumor tissue sample * Participants with sarcoma should have received no more than 2 lines of previous systemic therapies in the metastatic setting * Participants with selected epithelial solid tumors should have received no more than 3 lines of previous systemic therapy in the metastatic/relapsed refractory setting * Participants |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Zai Lab (Shanghai) Co., Ltd. |
| Locations | Los Angeles, California, United States; Sarasota, Florida, United States; St Louis, Missouri, United States; New York, New York, United States; Fairfax, Virginia, United States |
| Start date | 2026-03-02 |
| NCT ID | NCT07374848 |
| Official listing | https://clinicaltrials.gov/study/NCT07374848 |